US · POAI
Predictive Oncology Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Pittsburgh, MN 55121
- Website
- predictive-oncology.com
Price · as of 2024-12-31
—
Market cap 4.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $43.60 | — |
| Intrinsic Value(DCF) | $6.84 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $0.64 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $450,000.00 | $393,048.13 | $0.00 | $0.00 | $52,280.38 |
| 2011 | $483,750.00 | $2,355,254.70 | $2,925,635.62 | $0.00 | $0.00 |
| 2012 | $421,875.00 | $282,842.92 | $236,166,795.03 | $0.00 | $0.00 |
| 2013 | $1,237,500.00 | $504,915.73 | $20,980,633,704.42 | $0.00 | $0.00 |
| 2014 | $295,050.00 | $133,282.07 | $5,006,607,494.93 | $0.00 | $0.00 |
| 2015 | $13,500.00 | $8,845.61 | $1,037,462.51 | $0.00 | $6,661.35 |
| 2016 | $6,330.00 | $40,199.66 | $63,938.81 | $0.00 | $9,596.69 |
| 2017 | $4,044.00 | $1,629.32 | $36,025.69 | $0.00 | $0.00 |
| 2018 | $2,400.00 | $1,233.61 | $504,507.98 | $0.00 | $0.00 |
| 2019 | $747.00 | $765.35 | $92.91 | $0.00 | $0.00 |
| 2020 | $501.00 | $240.74 | $0.00 | $0.00 | $114.28 |
| 2021 | $279.00 | $126.54 | $25.50 | $0.00 | $0.00 |
| 2022 | $93.00 | $46.82 | $0.39 | $0.00 | $0.00 |
| 2023 | $43.65 | $36.92 | $1.15 | $0.00 | $0.00 |
| 2024 | $17.10 | $43.60 | $0.00 | $0.00 | $0.64 |
AI valuation
Our deep-learning model estimates Predictive Oncology Inc.'s (POAI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $43.60
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.84
— upside
Graham-Dodd
—
— upside
Graham Formula
$0.64
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| POAI | Predictive Oncology Inc. | $6.40 | 4.65M | +581% | +7% | — | -90% | -8.59 | -460.28 | 57.43 | -9.24 | — | -225.96 | 49.12% | -673.69% | -751.39% | -269.18% | -631.77% | -112.02% | -10.52 | — | 0.62 | 0.41 | -0.14 | -3563.00% | -878.00% | -1859.00% | -11.78% | -3.05 | -634.35% | 0.00% | 0.00% | 0.00% | -8.65 | -8.62 | 58.29 | -47.25 |
| AMIX | Autonomix Medical, Inc. C… | $0.84 | 4.3M | — | — | — | — | -0.23 | 0.32 | — | 0.59 | — | 0.32 | 0.00% | — | — | -145.10% | 2283.35% | -118.77% | 0.00 | -65.84 | 5.63 | 5.35 | 0.83 | -6937.00% | — | 2407.00% | -316.49% | -4.84 | 1629.95% | 0.00% | 0.00% | 58.54% | 0.56 | 0.79 | — | -9.21 |
| BNGO | Bionano Genomics, Inc. | $1.69 | 5.69M | +4,328% | -4% | — | +20,892% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| CYCN | Cyclerion Therapeutics, I… | $1.75 | 5.61M | — | +1,694,579% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| HSCS | HeartSciences Inc. | $2.90 | 6.52M | +667% | -43% | — | +20,854% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| KTTA | Pasithea Therapeutics Cor… | $0.73 | 5.47M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| MYNZ | Mainz Biomed B.V. | $1.42 | 5.81M | +15,965% | +58% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| TCRT | Alaunos Therapeutics, Inc… | $2.51 | 5.51M | +23,214% | -74% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| VYNE | VYNE Therapeutics Inc. | $0.34 | 5.63M | +7,029% | +1% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
About Predictive Oncology Inc.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
- CEO
- Raymond F. Vennare
- Employees
- 23
- Beta
- 1.33
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.84 ÷ —) − 1 = — (DCF, example).